GlassScriptPhysician profile
Nancy Kreyling
NPI 1750572715
$2,446.24
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $508 · 2023: $395 · 2024: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.52 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.32 | 2021-2024 | Enhertu |
| Janssen Biotech, INC. | $446.89 | 2022-2024 | Rybrevant, Darzalex, Talvey |
| Daiichi Sankyo INC. | $264.19 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $126.00 | 2024 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $124.60 | 2023 | |
| Gilead Sciences, INC. | $121.41 | 2024 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $120.28 | 2022 | |
| Abbvie INC. | $115.86 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $115.51 | 2022 | |
| Karyopharm Therapeutics INC. | $100.01 | 2022 | |
| Amgen INC. | $97.00 | 2021 | |
| Incyte Corporation | $95.39 | 2021 | |
| Eisai INC. | $94.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $44.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Kreyling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.